# CVS HEALTH Corp: Form 10-Q for the period ended Jun 30, 2017

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2017-08-08
- Accepted by EDGAR: Aug 8, 2017, 07:16 ET
- Period: 2017-06-30
- Accession: 0001558370-17-006198
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000155837017006198/cvs-20170630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000155837017006198/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-04-01 to 2017-06-30 | $45.69bn | us-gaap:Revenues |
| Revenue | 6 months, 2017-01-01 to 2017-06-30 | $90.20bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2017-04-01 to 2017-06-30 | $38.75bn | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2017-01-01 to 2017-06-30 | $76.68bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2017-04-01 to 2017-06-30 | $6.93bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2017-01-01 to 2017-06-30 | $13.52bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | $2.12bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-01-01 to 2017-06-30 | $3.91bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2017-04-01 to 2017-06-30 | $766.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2017-01-01 to 2017-06-30 | $1.34bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | $1.10bn | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | $2.05bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | $1.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | $1.98 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-04-01 to 2017-06-30 | $1.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2017-01-01 to 2017-06-30 | $1.99 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-04-01 to 2017-06-30 | 1,024,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2017-01-01 to 2017-06-30 | 1,029,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2017-01-01 to 2017-06-30 | $5.53bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2017-01-01 to 2017-06-30 | $888.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2017-01-01 to 2017-06-30 | $1.03bn | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months, 2017-01-01 to 2017-06-30 | $3.96bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2017-06-30 | $2.09bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $29.40bn | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $92.53bn | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $26.86bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2017-06-30 | $25.62bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-06-30 | $42.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2017-06-30 | $1.10bn | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2017-06-30 | $34.14bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 1,129 characters.

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended June 30, 2017, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2016 Repurchase Program. See “Note 3 - Share Repurchase Programs” contained in the “Notes to the Condensed Consolidated Financial Statements” of our Quarterly Report on Form 10‑Q for the three months ended June 30, 2017.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| April 1, 2017 through April 30, 2017 | 9,929,480 | $72.93 | 9,929,480 | $14,609,385,267 |
| May 1, 2017 through May 31, 2017 | 1,822,400 | $76.82 | 1,822,400 | $14,469,392,413 |
| June 1, 2017 through June 30, 2017 | 2,543,704 | $78.63 | 2,543,704 | $14,269,392,432 |
|  | 14,295,584 |  | 14,295,584 |  |

40

## Market risk

As filed, 335 characters.

As of June 30, 2017, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes that as of June 30, 2017 its exposure to interest rate risk (inherent in the Company’s debt portfolio), foreign currency exchange rate risk and commodity price risk is not material.

## Controls and procedures

As filed, 1,054 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a‑15(f) and 15d‑15(f)) as of June 30, 2017, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a‑15 or Rule 15d‑15 that occurred in the three months ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

39

Filed Aug 8, 2017.
Source: SEC EDGAR, the filing index for accession 0001558370-17-006198. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
